trevena_final.png
Trevena Announces Receipt of Nasdaq Delisting Notification
October 04, 2024 16:05 ET | Trevena, Inc.
CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
trevena_final.png
Trevena Announces Reverse Stock Split
August 08, 2024 16:05 ET | Trevena, Inc.
CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
trevena_final.png
Trevena Reports Second Quarter 2024 Results and Provides Business Update
August 08, 2024 07:00 ET | Trevena, Inc.
TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism...
trevena_final.png
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
July 08, 2024 09:15 ET | Trevena, Inc.
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further...
trevena_final.png
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
June 20, 2024 07:00 ET | Trevena, Inc.
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant,...
trevena_final.png
Trevena Reports First Quarter 2024 Results and Provides Business Update
May 15, 2024 07:00 ET | Trevena, Inc.
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances,...
trevena_final.png
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
April 01, 2024 07:00 ET | Trevena, Inc.
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial...
trevena_final.png
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
December 28, 2023 14:00 ET | Trevena, Inc.
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel...
trevena_final.png
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
December 27, 2023 09:10 ET | Trevena, Inc.
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel...
trevena_final.png
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
December 04, 2023 07:02 ET | Trevena, Inc.
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045...